Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (January 2026)
31 slides from Cytosorbents's investor presentation, January 2026
Slide 1: Investor Presentation January 2026
NASDAQ: CTSO Investor Presentation January 2026 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: Regulatory Disclaimer
Regulatory Disclaimer CytoSorb DrugSorb-ATR • CE Marked in Europe for the following APPROVED • INVESTIGATIONAL DEVICE: Limited by U.S. Federal Indications for Use: Law to Investigational Use Only • Cytokine Removal • Bilirubin and Myoglobin Removal • This Investigational Device is NOT yet cleared/ap
Slide 4: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology to remove toxins and harmful substances from the blood • High margin “razorblade” that we manufacture in the U.S. and is “plug and play” into existing hospital blood pumps CytoSorb • Used to treat life-threatening conditions in the IC
Slide 5: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 6: Products are "Plug and Play" Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) ECMO CPB (Extracorporeal Membrane Oxygenation) (Cardiopulmonary Bypass) 6 | CytoSorbents Confiden
Slide 7: CytoSorb
CytoSorb Our Core Business CytoSorb is EU CE mark approved but not yet cleared or approved in the U.S./Canada 7 |
Slide 8: CytoSorb is Expanding the Dimension of Blood Purification
CytoSorb is Expanding the Dimension of Blood Purification CytoSorb is a powerful blood purification technology CE-mark approved in the E.U. to reduce cytokines, bilirubin, myoglobin, and blood thinners like ticagrelor & rivaroxaban. It can remove many substances that dialysis cannot. CytoSorb is des
Slide 9: Uncontrolled Massive Inflammation - the Heart of Critical Illness
Uncontrolled Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE SHOCK
Slide 10: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 11: CytoSorb Has Much Larger ICU Opportunity than Dialysis
CytoSorb Has Much Larger ICU Opportunity than Dialysis Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory High r
Slide 12: CytoSorb Supported by a Wealth of Clinical Data
CytoSorb Supported by a Wealth of Clinical Data 12 | Voices around the world
Slide 13: Sepsis and Septic Shock are Deadly
Sepsis and Septic Shock are Deadly • Sepsis is a complex life-threatening condition where the inflammatory response to a serious infection can spiral out of control, fueled by the excessive production of cytokines (cytokine storm), bacterial toxins, and other inflammatory agents • Unchecked, massive
Slide 14: CytoSorbents is Leading a New Era in Sepsis Treatment
CytoSorbents is Leading a New Era in Sepsis Treatment For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broad-spectrum capability of CytoSorb Cyto
Slide 15: CytoSorb Enables Multi-Faceted Attack on Septic Shock
CytoSorb Enables Multi-Faceted Attack on Septic Shock A wealth of published, peer-reviewed studies support the broad mechanisms of action of CytoSorb that enable a comprehensive and multi-faceted attack on septic shock – from beginning to end CytoSorb reduces Cytokines and other Inflammatory Toxins
Slide 16: The Key to Success: Right Patient, Right Timing, Right Dosing
The Key to Success: Right Patient, Right Timing, Right Dosing Right Patient Just like antibiotics, CytoSorb works most effectively when: Highest • Treat Early Chance for • Treat Intensively Good Cinical • Compete the Full Course of Treatment Outcome Right Right Timing Dose 16 | CytoSorb is EU CE mar
Slide 17: 2025: COSMOS Registry Highlights Treatment Strategy Success
2025: COSMOS Registry Highlights Treatment Strategy Success COSMOS registry, patient characteristics CAPILLARY LUNG • Data from 150 patients analyzed SHOCK LEAK FUNCTION • Critical care indications: Septic shock (57.6%) Cardiogenic shock (12.9%) Rhabdomyolysis (10.6%) Acute/acute-on-chronic liver fa
Slide 18: 2025: Early & Intensive Treatment with More Blood Treated Works Best
2025: Early & Intensive Treatment with More Blood Treated Works Best • Large, retrospective single center study • 175 patients with septic shock treated with CytoSorb • Evaluated the impact of early versus late, and low versus high intensity treatment with CytoSorb on mortality compared to predicted
Slide 19: CytoSorb Improves Survival in Septic Shock Meta-Analysis
CytoSorb Improves Survival in Septic Shock Meta-Analysis • Steindl, et al. (2025) from Charite in Berlin conducted a large meta-analysis of 744 septic shock patients from 1 RCT and 8 observational studies from 2019-2024, of which 449 patients were treated with CytoSorb • CytoSorb use was associated
Slide 20: Turning the Tide of Sepsis and Septic Shock: Real World Insights
Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb September 10, 2025 Link to webinar replay: https://cyto.news/webinar-sepsis/sep10 20 |
Slide 21: The Opportunity of DrugSorb-ATR
The Opportunity of DrugSorb-ATR s an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale 21 |
Slide 22: Blood Thinners Can Cause Serious Perioperative Bleeding
Blood Thinners Can Cause Serious Perioperative Bleeding • Millions of people are on blood thinners to reduce their risk of heart attack and stroke • However, if urgent, unscheduled surgery is required, they risk serious perioperative bleeding • For example, acute heart attack patients commonly recei
Slide 23: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb- ATR is to allow patients to get the critical surgery they need without delay while reducing or preventing X X XX X bleeding complications 23 | DrugSorb-ATR is an investigational device in the U.S. and
Slide 24: Seeking De Novo Authorization for DrugSorb-ATR
Seeking De Novo Authorization for DrugSorb-ATR • U.S. & Canadian randomized controlled pivotal STAR-T trial established DrugSorb-ATR as a De Novo 510(k) eligible device, DrugSorb-ATR must show that its probable benefits outweigh its probable risks to gain market clearance • Our initial De Novo submi
Slide 25: FDA Regulatory Timeline
FDA Regulatory Timeline • On November 7, 2025, we filed a formal Pre-Submission Meeting Request with supporting documentation • A Pre-Submission Meeting is scheduled for this month and is expected to confirm FDA requirements for the new De Novo application • Expect to file a new De Novo Filing this
Slide 26: Financial Performance
26 Financial Performance CytoSorbents.
Slide 27: CytoSorb Commercialization Focus
CytoSorb Commercialization Focus • We sell CytoSorb in more than 70 countries worldwide with nearly 300,000 treatments to date • Sell Direct in Germany and 8 other countries & through Distributors and partners in the remainder Estimated Revenue By Market Revenue By Geography Other Critical Care: 17%
Slide 28: Targeting Acceleration of Annual Revenue Growth
Targeting Acceleration of Annual Revenue Growth $45.0 Annual Product Sales Revenue $40.0 $39.5M $40.1M • 2025 full year revenue estimated to be $37.0M $6.3 $9.4 $35.6M $37.0M, +4% vs $35.6M in 2024 $37.0 $35.0 $35.6 $33.8 $31.1M $30.0 $29.4M $31.1 $30.1 Estimated Gross Margins $29.1 $ IN MILLONS $25
Slide 29: Strengthened Balance Sheet and Path to Profitability
Strengthened Balance Sheet and Path to Profitability • Accelerating the path to profitability has continued to be a key priority • Implemented a previously announced strategic workforce and cost reduction program in the fourth quarter and expect to be approximately cash-flow breakeven (excluding res
Slide 30: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition We believe we are significantly undervalued with a sound plan to build and maximize shareholder value CytoSorb is an established, international core business in critical care and cardiac surgery with $37M in high margin product sales and an excellent “razorbl
Slide 31: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com www.cytosorbents.com 31